ImmuPharma (LON:IMM) Trading Up 9.5% - Still a Buy?

Key Points

• ImmuPharma's stock surged by 9.5% on Wednesday, reaching GBX 14.20 ($0.19) at its peak, with trading volume increasing by 176% compared to its average daily volume.
• The company has a market cap of £58.22 million and reported an EPS of GBX (0.38) for the last quarter, with analysts predicting a significantly negative EPS for the current fiscal year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program targeting Lupus, which shows promise based on preclinical results.

ImmuPharma plc (LON:IMM - Get Free Report) was up 9.5% on Wednesday . The company traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). Approximately 23,646,498 shares changed hands during mid-day trading, an increase of 176% from the average daily volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Price Performance

The firm has a market cap of £58.22 million, a P/E ratio of -1,308.99 and a beta of 1.53. The stock's 50 day moving average is GBX 4.66 and its two-hundred day moving average is GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.